Sinusoidal obstruction syndrome historical perspective: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 13: Line 13:
* Endophlebitis in the terminal hepatic venule was first described by a pathologist from Prague in 1905.<ref name="pmid25755580">{{cite journal| author=Fan CQ, Crawford JM| title=Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). | journal=J Clin Exp Hepatol | year= 2014 | volume= 4 | issue= 4 | pages= 332-46 | pmid=25755580 | doi=10.1016/j.jceh.2014.10.002 | pmc=4298625 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25755580  }} </ref>
* Endophlebitis in the terminal hepatic venule was first described by a pathologist from Prague in 1905.<ref name="pmid25755580">{{cite journal| author=Fan CQ, Crawford JM| title=Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). | journal=J Clin Exp Hepatol | year= 2014 | volume= 4 | issue= 4 | pages= 332-46 | pmid=25755580 | doi=10.1016/j.jceh.2014.10.002 | pmc=4298625 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25755580  }} </ref>
* In the 1960s, studies on effects of hepatic vasculature by ionizing radiations were reported.  <ref name="pmid1980552">{{cite journal |vauthors=Dormoy A, Urlacher A, Tongio MM |title=A nucleotide substitution in a Bg1 II site is responsible for the RFLP discrimination between DPw4 and DPa |journal=Tissue Antigens |volume=36 |issue=3 |pages=129–35 |year=1990 |pmid=1980552 |doi= |url=}}</ref><ref name="pmid13984193">{{cite journal |vauthors=STIRLING GA, BRAS B, URQUHART AE |title=The early lesions in veno-occlusive disease of the liver |journal=Arch. Dis. Child. |volume=37 |issue= |pages=535–8 |year=1962 |pmid=13984193 |pmc=2012933 |doi= |url=}}</ref>
* In the 1960s, studies on effects of hepatic vasculature by ionizing radiations were reported.  <ref name="pmid1980552">{{cite journal |vauthors=Dormoy A, Urlacher A, Tongio MM |title=A nucleotide substitution in a Bg1 II site is responsible for the RFLP discrimination between DPw4 and DPa |journal=Tissue Antigens |volume=36 |issue=3 |pages=129–35 |year=1990 |pmid=1980552 |doi= |url=}}</ref><ref name="pmid13984193">{{cite journal |vauthors=STIRLING GA, BRAS B, URQUHART AE |title=The early lesions in veno-occlusive disease of the liver |journal=Arch. Dis. Child. |volume=37 |issue= |pages=535–8 |year=1962 |pmid=13984193 |pmc=2012933 |doi= |url=}}</ref>
* The concept of sinusoidal obstruction syndrome induced by either chemical or radiation toxicity was well established by mid-1960s as a separate entity from Budd-Chiari syndrome.<ref name="pmid13827970">{{cite journal |vauthors=GIBSON JB |title=Chiari's disease and the Budd-Chiari syndrome |journal=J Pathol Bacteriol |volume=79 |issue= |pages=381–401 |year=1960 |pmid=13827970 |doi= |url=}}</ref>




Revision as of 14:17, 4 January 2018

Sinusoidal obstruction syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sinusoidal obstruction syndrome from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sinusoidal obstruction syndrome historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sinusoidal obstruction syndrome historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sinusoidal obstruction syndrome historical perspective

CDC on Sinusoidal obstruction syndrome historical perspective

Sinusoidal obstruction syndrome historical perspective in the news

Blogs on Sinusoidal obstruction syndrome historical perspective

Directions to Hospitals Treating Sinusoidal obstruction syndrome

Risk calculators and risk factors for Sinusoidal obstruction syndrome historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Historical Perspective

  • Endophlebitis in the terminal hepatic venule was first described by a pathologist from Prague in 1905.[1]
  • In the 1960s, studies on effects of hepatic vasculature by ionizing radiations were reported. [2][3]
  • The concept of sinusoidal obstruction syndrome induced by either chemical or radiation toxicity was well established by mid-1960s as a separate entity from Budd-Chiari syndrome.[4]




Template

  • First Sentence:
[Disease name] was first discovered by [scientist] in [year] during/following [event].
OR
[Disease name] was first described by [scientist] in [year].
  • Examples:
Example 1:Shigella was first discovered by Dr. Kiyoshi Shiga following a bacillary dysentery outbreak in Japan in 1896.
Example 2: Melanoma was first described by Hippocrates in the 5th century BC.


  • Additional Sentences:
Additional Sentence 1: In [year], the first [event] occurred/was first reported following/during [event].
Additional Sentence 2: In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
Additional Sentence 3: There have been several outbreaks of [disease] which are summarized below.
Additional Sentence 4: [Disease name] was first described in [year] by [scientist].
Additional Sentence 5: [Risk factor or cause] was first discovered to be associated with [disease] in [year].
Additional Sentence 6: In [year], [scientist] was the first to discover the association between [risk factor] and development of [disease].
Additional Sentence 7: In [year], [gene] mutations were first identified in the pathogenesis of [disease].
  • Examples:
Example 1: In 1918, the first major human influenza pandemic occurred.
Example 2: In 2003, human-to-human transmission of avian influenza was first reported during the influenza A H5N1 outbreaks in Southeast and Central Asia.
Example 3: In 1978, the first cell-cytotoxicity assay was developed by Te-Wen Chang to diagnose C. difficile infection based on fecal toxins A and B.
Example 4: There have been several outbreaks of avian influenza which are summarized below.
Example 5: In 1956, Henry Lancaster, an Australian mathematician, was the first to discover the association between UV radiation exposure and development of melanoma.
Example 6: In 2003, BRAF mutations were first identified in the pathogenesis of melanoma.

References

  1. ↑ Fan CQ, Crawford JM (2014). "Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)". J Clin Exp Hepatol. 4 (4): 332–46. doi:10.1016/j.jceh.2014.10.002. PMC 4298625. PMID 25755580.
  2. ↑ Dormoy A, Urlacher A, Tongio MM (1990). "A nucleotide substitution in a Bg1 II site is responsible for the RFLP discrimination between DPw4 and DPa". Tissue Antigens. 36 (3): 129–35. PMID 1980552.
  3. ↑ STIRLING GA, BRAS B, URQUHART AE (1962). "The early lesions in veno-occlusive disease of the liver". Arch. Dis. Child. 37: 535–8. PMC 2012933. PMID 13984193.
  4. ↑ GIBSON JB (1960). "Chiari's disease and the Budd-Chiari syndrome". J Pathol Bacteriol. 79: 381–401. PMID 13827970.

Template:WS Template:WH

Retrieved from "https://www.wikidoc.org/index.php?title=Sinusoidal_obstruction_syndrome_historical_perspective&oldid=1427428"